Literature DB >> 10993397

Intervention research in psychosis: issues related to the assessment of quality of life.

A G Awad1, L N Voruganti.   

Abstract

Quality of life has emerged as the ideal of modern medicine viewed from a biopsychosocial perspective. The concept has been increasingly used as an important attribute in patient care and clinical studies as well as the basis in many health economic evaluations. Although the concept has been extensively applied in a number of other medical fields such as oncology, cardiovascular, and arthritis, it is only recently that quality of life has received serious attention in the study of severe psychiatric disorders. For the concept to be meaningfully applied in the study of these disorders, several basic and methodological issues have to be adequately resolved. Five such issues are identified: definition of quality of life, the subjective/objective dichotomy, significant determinants of quality of life, how quality of life is measured, and the role of quality of life in clinical management and health economics. Unless these issues are adequately clarified and resolved, the recent heightened interest in the concept of quality of life may fade away, and that would be a missed opportunity in the mental health field.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993397     DOI: 10.1093/oxfordjournals.schbul.a033477

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  20 in total

1.  Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation.

Authors:  Arielle W Tolman; Matthew M Kurtz
Journal:  Schizophr Bull       Date:  2010-07-11       Impact factor: 9.306

2.  Impact of untreated psychosis on quality of life in patients with first-episode schizophrenia.

Authors:  C W Law; Eric Y H Chen; Eric F C Cheung; Raymond C K Chan; Josephine G W S Wong; Cindy L K Lam; K F Leung; Molly S M Lo
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

3.  Clinical characteristics and objective living conditions in relation to quality of life among community-based individuals of schizophrenia in Hong Kong.

Authors:  Frederick Ka Ching Yeung; Sunny Ho Wan Chan
Journal:  Qual Life Res       Date:  2006-09-07       Impact factor: 4.147

4.  Determinants of changes in perceived quality of life in the course of schizophrenia.

Authors:  Michael Ritsner; Anatoly Gibel; Yael Ratner
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

5.  Psychometric evaluation of the Danish and Swedish Satisfaction with Life Scale in first episode psychosis patients.

Authors:  Jacek Hochwälder; Maria Mattsson; Ragnhild Holmqvist; Johan Cullberg; Bent Rosenbaum
Journal:  Qual Life Res       Date:  2012-05-15       Impact factor: 4.147

Review 6.  Measuring quality of life in patients with schizophrenia: an update.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

7.  Subjective versus interviewer assessment of global quality of life among persons with schizophrenia living in the community: a Nordic multicentre study.

Authors:  Anita Bengtsson-Tops; Lars Hansson; Mikael Sandlund; Olafur Bjarnason; Jyrki Korkeila; Lars Merinder; Liselotte Nilsson; Knut Wollo Sørgaard; Hanne R Vinding; Thomas Middelboe
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

Review 8.  Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Patients' subjective experiences of antipsychotics: clinical relevance.

Authors:  Jonathan S E Hellewell
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 10.  The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.